Return to search

Combating fibrosis in mdx mice with a novel antifibrosis drug - Halofuginone

The effects of the antifibrotic drug Halofuginone hydrobromide (Halo) on muscle function, regeneration and cardiorespiratory function were studied using mdx mice. It was hypothesized that Halo treatment would resolve pre-established fibrosis and prevent collagen deposits, improving muscle and cardio-respiratory function.
Mice 8-9 mos were treated with saline or Halo for 5 (n = 4/group), 10 (n = 5/group) and 12 weeks (n = 4-5/group). Muscle strength and endurance, respiration and muscle susceptibility to damage were assessed. Tissues were collected from all mice. Additional mice were treated for 10 wks (3-4 wks n = 9-10/group; 8-9 mos n = 8-9/group) for echocardiography.
Halo reduced fibrosis. As a consequence, there was muscle repair and damage was reduced. There were functional improvements and disease progression was slowed. There was resolution of pre-existing fibrosis and reduction of new collagen synthesis. This treatment could improve quality of life and lengthen the lifespan of DMD patients. / May 2007

  1. http://hdl.handle.net/1993/329
Identiferoai:union.ndltd.org:LACETR/oai:collectionscanada.gc.ca:MWU.anitoba.ca/dspace#1993/329
Date26 April 2007
CreatorsHuebner, Kyla Danielle
ContributorsAnderson, Judith (Human Anatomy and Cell Science), Thliveris, James (Human Anatomy and Cell Science) Scott, Elliott (Oral Biology)
Source SetsLibrary and Archives Canada ETDs Repository / Centre d'archives des thèses électroniques de Bibliothèque et Archives Canada
Languageen_US
Detected LanguageEnglish
Format25937408 bytes, 5231616 bytes, 1483776 bytes, 8609280 bytes, 2305819 bytes, application/octet-stream, application/octet-stream, application/octet-stream, application/octet-stream, application/pdf

Page generated in 0.0019 seconds